The only FDA-approved treatment in which daily soft lenses that are clinically proven to slow the progression of myopia.
Years 1-3 proved that MiSight® 1 day slows myopia progression in age-appropriate children by 59% on average.
Part 1 of the study assessed the difference in myopia progression between MiSight® 1 day and single vision 1 day lenses. This part of the study showed that over the 3 years, MiSight® 1 day reduced the rate of myopia progression by 59% and axial elongation by 52% on average, in children aged 8-12 at the initiation of treatment.
Year 4-6 underscored that MiSight® 1 day works as effectively for new and established age-appropriate wearers.
Part 2 of the study compared the rate of myopia progression between children new to MiSight® 1 day and those wearing MiSight® 1 day for the previous 3 years. This comparison found that new and established MiSight® 1 day wearers have comparable rates of myopic progression and axial length growth.2 These findings suggest that while intervention at an early age is optimal with MiSight® 1 day, commencing treatment at an older age can still slow the rate of myopia progression just as effectively.
Currently there is a part 3 study presenting results after 7 years which will be presented at the end of 2021.